Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib adjuvant therapy after surgery for high-risk recurrent hepatocellular carcinoma
ChiCTR2500095924Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lenvatinib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: 1-year cumulative recurrence-free patient percentage. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2500095924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095924.